maximize the overall therapeutic benefi t of gene therapy for HIV and genetic diseases where high levels of gene-modifi ed T lymphocytes are necessary to alleviate all clinical manifestations of the disease.
Acute Intrahepatic CD8 T Cell Activation by Plasmid DNA Induces Defective CD8 T Cell Immune Response
Nyamekye Obeng-Adjei, 1 Daniel K. Choo, 1 David B. Weiner. 1 1 Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
The fate of CD8 T cells primed in the liver has been a subject of controversy in the attempt to explain the failure of immunity in chronic liver infections such as HBV, HCV and malaria. While most models show activation of CD8 T cells when liver resident cells present antigen, there are differences in opinion as to what becomes of these T cells after their initial priming. In this study, we used hydrodynamic injection that mimics acute HBV/HCV infection to express antigen in the liver, while taking advantage of the wellestablished LCMV P14 system, to induce acute intrahepatic T cells activation. We observed comparable CD8 T cells proliferation, upregulation of CD44 and CD25, down-regulation of L-selectin, to the control (activation in lymphoid tissues). However, CD8 T cells primed in the liver expressed higher levels of pro-apoptotic markers such as Bim and active caspase 3, resulting in the loss of activated cells in all tissues. These liver activated CD8 T cells were incapable of protecting mice from lethal intracranial LCMV challenge. Our results confi rm the up-regulation of 'death markers' during CD8 T cell priming in the liver, which leads to deletion of activated CD8 T cells needed to control viral infections in the liver. Thus, the failure of T cells to control chronic HBV/HCV is more likely due to defective liver priming of antigen-specifi c T cells. The design of efficient bacteria-based vectors for vaccine platforms and cancer gene therapy is an area of intensive research with 12 vectors currently in clinical testing (http://www.wiley.co.uk/ genmed/clinical/). Genetically engineered bacteria have found limited application in the fi eld due to their inability to survive long term under extreme environmental conditions. Our laboratory recently found that buccal administration of an adenovirus-based vaccine fostered potent antigen-specifi c immune responses that could provide protection against lethal Ebola infection in naïve mice and Guinea pigs and those with prior exposure to the adenovirus carrier (Choi et al., Mol. Pharm. 2012 9(1):156-67). Buccal delivery would promote patient compliance and may be useful if multiple dosing is required or pre-existing immunity is found to be an issue with bacterial vectors. These studies were designed to test the hypothesis that once a bacterial vaccine candidate is placed in a preservative solution and dried as a fi lm under optimized conditions, it can be stored in an amorphous state for long periods of time and placed directly on a mucosal surface for effective immunization. Criteria considered to optimize the novel vaccine are: formulation composition, nature of drying surface, storage temperature, and moisture content. Three types of excipients were evaluated for their abilities to preserve bacteria. The formulations are summarized in Table 1 in a partial 4×6 factorial design. Formulated bacteria were either placed on a hard solid surface (CS, Ted Pella, Inc) or fl exible fi lm (PS, Argotec). Twenty-four hours after drying at ambient temperature, preparations were resuspended in saline. Concentrations of each preparation prior to drying and after reconstitution were used to compare recovery effi ciency of each formulation. 
A Solid Dosage Form for Buccal Delivery of Bacteria-Based Vaccines: Role of Excipients, Crystallinity and Drying Surface
Formulations on the fi lm required a longer drying period (4h vs. 2h). Despite this, use of the fi lm backing was directly associated with signifi cantly higher recovery of active bacteria with respect to that from the hard surface. Formulations containing sucrose supported the highest recovery from the fi lm. There was no difference in recovery with respect to sugar on the hard surface. Some of the most effective formulations on either surface were amorphous and some were crystalline. The crystallinity of these formulations was dictated by the type of surfactant included in the preparation. One formulation has been identifi ed for additional in vivo testing. The long-term stability of fi lms at ambient temperatures will also be discussed. First-in-human clinical trials (ClinicalTrials.gov Identifiers: NCT00968760) using Sleeping Beauty (SB) transposition to introduce a chimeric antigen receptor (CAR) as transposon into autologous and allogeneic T cells for investigational treatment of high-risk B-cell malignancies patients are under way at the University of Texas MD Anderson Cancer Center. We have employed next generation sequencing (NGS) (Illumina) and profi ling (BlueBioU supercomputer) of the unique 687,176 (9.24 %) SB insertion sites of total 7,436,108 raw reads from 33 separate gene transfer events to generate CAR+ T cells. We demonstrate that SB integration profi les compare favorably with retroviral and lentiviral insertions. Transposed vectors inserted 99% of the time at expected TA dinucleotide sites with intragenic insertions (39% of total) concentrated in intronic sequences (96.5%), while intergenic insertions (61% of total) were dispersed in unique and non-coding repeat regions. To address the potential genotoxic risks and thus safety issue here we linked gene expression and miRNA profi ling with NGS insertion profi les to assess potential genotoxic risks SB-mediated transposition of DNA plasmid. Global mRNA (Illumina) and miRNA (nanoString) expression profi les from unmodifi ed CARneg (quiescent) and ex vivo propagated (activated) CAR+ T cells closely matched published quiescent and activated expression profi les. By linking gene expression profi les and sequencing datasets, we fi nd that the number of transcriptional start sites (TSS) containing a transposon is proportional to the expected 'open' conformational loci for the starting population of quiescent T cells and preferred at a ratio of 3 (quiescent) to 1 (activated). In addition, most insertions (>90%) are found to be more than 50 Kb away from miRNA loci. Scanning for potential danger loci (e.g. oncogene, tumor suppressor, miRNA, CpG island etc.), SB integration profi les compare favorably with retroviral and lentiviral insertions. In addition, we identifi ed potential "safe harbor" genetic loci for future targeted modifi cations. Based on a combination of NGS, mRNA, and miRNA data from preclinical samples we plan to establish a basal molecular signature for SB-modifi ed T cells and generate a quantitative risk metrics for long-term follow-up of immunotherapy patients. Based on these data sets we seek to proactively profi le the T-cell products prior to infusion and follow-up samples to provide clinicians with tools regarding the genetic data of the infusion product. Our methods and fi ndings are consistent with the human application of SB system and the harnessing high throughput supercomputing resources to help clinicians mitigate potential risks. Gene modifi ed, cell-based cancer vaccines have demonstrated durable responses in selected patients. We have conducted two Phase I studies with vaccines made of autologous tumor cells transfected with either a TAG plasmid (expressing GM-CSF and a TGFβ 2 antisense) or a novel FANG™ plasmid (expressing GM-CSF and a proprietary bifunctional shRNA to Furin that knocks down Furin expression thereby knocking down both TGFβ1 and TGFβ2). These autologous vaccines embody the 'triad' concept; the use of 1) patientspecifi c tumor antigens, 2) GMCSF to enhance the afferent arm of the immune response, and 3) pbi-shRNA™ Furin to inhibit endogenous cancer cell immunosuppression. Aliquots of tumor cells before and after transfection with plasmid were removed and stored frozen to be able to assess the IFNγ immune response in treated patients. Patients could be treated with up to 12 monthly intradermal vaccine doses depending on the quantity of accessed tissue that determined the number of doses available. Blood samples were collected at baseline and at Months 3, 6, end of treatment and at follow up visits for TAG vaccine treated patients. For FANG™ vaccine treated patients the time points for blood collection were baseline, Months 4, 6, 9, end of treatment and at quarterly follow up visits. PBMCs (peripheral blood mononuclear cells) were separated by Ficoll™ Gradient and frozen. The immune response of T-cells to the administered TAG or FANG™ vaccines was assessed by IFNγ-ELISPOT assay. Immune responsiveness was evaluated with PMA/Ionomysin (a mutagen) in pre-and post-plasmid transfected tumor cells. TAG vaccine results: Twenty-three (23) patients who received at least 3 TAG vaccines (TGFb2 knockdown, 54%) were analyzed for immune response. Eleven of 23 patients displayed a positive ELISPOT response to autologous TAG vaccine at Month 3, of whom 6 patients remain alive (3 of these patients have prolonged stable disease or complete response). Twelve patients displayed a negative ELISPOT, of whom 2 patients survived, coming off treatment after 4 and 11 vaccines. The ELISPOT response correlation with survival duration was not statistically signifi cant although a trend was noted (p=0.083). FANG™ vaccine results: Eighteen (18) patients who received at least 4 FANG TM vaccines and demonstrated effective knockdown of both TGFb1 and b2 (93.5% and 92.5%, respectively), were analyzed for immune response by ELISPOT assay. At Month 4, 9 out of 18 patients had a positive ELISPOT response that correlated with survival duration from time of treatment (p=0.025) (Senzer N. et al. Mol Ther, 2011) . Furthermore, longer term IFNg-ELISPOT assays in 8 of the 9 patients show a sustained immune response. GMCSF expression was similar between both vaccine groups.
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